Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1449-1458

  Beer, Sandra ^a   Feihl, François ^a   Ruiz, Juan ^a   Juhan Vague, Irène ^b   Aillaud, Marie Françoise ^b   Wetzel, Sandrine Golay ^a   Liaudet, Lucas ^a   Gaillard, Rolf C ^a   Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Hemostatic markers; Iontophoresis; Pulse wave velocity; Skin microcirculation; Type 2 diabetes

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITROPRUSSIDE SODIUM; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; FOREARM BLOOD FLOW; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPEREMIA; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; SKIN BLOOD FLOW;

ADMINISTRATION, CUTANEOUS; AGED; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HEMOSTASIS; HOT TEMPERATURE; HUMANS; HYPEREMIA; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; PULSATILE FLOW; REGIONAL BLOOD FLOW; SKIN; VASODILATION; VASODILATOR AGENTS;

EID: 60249086595     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Alberti KG, Zimmet PZ. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab Med, 15:539-53.
2. American Diabetes Association. 2001. Standards of medical care for patients with diabetes mellitus. Diabetes Care, 24 (Suppl 1):33-55.
3. Amos AF, McCarty DJ, Zimmet P. 1997. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diab Med, 14:S1-85.
4. Anderson TJ. 1999. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol, 34:631-8.
5. Asmar R, Benetos A, Topouchian J, et al. 1995. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension, 26:485-90.
6. Aso Y, Fujiwara Y, Tayama K, et al. 2002. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diab Med, 19:19-26.
7. Bagg W, Ferri C, Desideri G, et al. 2001. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. J Clin Endocrinol Metab, 86:541-7.
8. Beer S, Golay S, Bardy D, et al. 2005. Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type2 diabetic patients with vascular complications. Diab Metab, 31:567-73.
9. Berghoff M, Kathpal M, Kilo S, et al. 2002. Vascular and neural mechanisms of ACh-mediated vasodilation in the forearm cutaneous microcirculation. J Appl Physiol, 92:780-8.
10. Blann AD, McCollum CN, Lip GY. 2002. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis, 13:513-8.
11. Brunner H, Cockcroft JR, Deanfield J, et al. 2005. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:233-46.
12. Caballero AE, Arora S, Saouaf R, et al. 1999. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes, 48:1856-62.
13. Caballero AE. 2003. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res, 11:1278-89.
14. Calles-Escandon J, Cipolla M. 2001. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev, 22:36-52.
15. Cines DB, Pollak ES, Buck CA, et al. 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood, 91:3527-61.
16. Collier A, Rumley A, Rumley AG, et al. 1992. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes, 41:909-13.
17. Consensus Development Conference on Insulin Resistance. American Diabetes Association. 1998. Diabetes Care, 21:310-4.
18. Cruickshank K, Riste L, Anderson SG, et al. 2002. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation, 106:2085-90.
19. Deanfield J, Donald A, Ferri C, et al. 2005. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:7-17.
20. Ding H, Triggle CR. 2005. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag, 1:55-71.
21. Erem C, Hacihasanoglu A, Celik S, et al. 2005. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract, 14:22-30.
22. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003. J Hypertens, 21:1011-53.
23. Feletou M, Vanhoutte PM. 2006. Endothelial dysfunction: a multifaceted disorder. Am J Physiol Heart Circ Physiol, 291:H985-H1002.
24. Gerstein HC, Mann JF, Yi Q, et al. 2001. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 286:421-6.
25. Glanz SA. 1992. Primer of biostatistics. 3rd ed. New York: McGraw-Hill. pp. 350-2.
26. Golay S, Haeberli C, Delachaux A, et al. 2004. Local heating of human skin causes hyperemia without mediation by muscarinic cholinergic receptors or prostanoids. J Appl Physiol, 97:1781-6.
27. Henry RM, Kostense PJ, Spijkerman AM, et al. 2003. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation, 107:2089-95.
28. Hogikyan RV, Galecki AT, Pitt B, et al. 1998. Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab, 83:1946-52.
29. Jaap AJ, Hammersley MS, Shore AC, et al. 1994. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologica, 37:214-6.
30. Jaap AJ, Shore AC, Tooke JE. 1997. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia, 40:238-43.
31. Jermendy G, Farkas K, Nadas J, et al. 2001. Practical aspects of measuring microalbuminuria in diabetic patients. Diab Nutr Metab, 14:195-200.
32. Kario K, Matsuo T, Kobayashi H, et al. 1995. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Anterioscler Thromb Vasc Biol, 15:1114-20.
33. Kathiresan S, Gona P, Larson MG, et al. 2006. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation, 113:938-45.
34. Kato H. 2002. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arteriosclerosis Thromb Vasc Biol, 22:539-48.
35. Kellogg DL, Jr, Liu Y, Kosiba IF, et al. 1999. Role of nitric oxide in the vascular effects of local warming of the skin in humans. J Appl Physiol, 86:1185-90.
36. Kim JA, Montagnani M, Koh KK, et al. 2006. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 113:1888-904.
37. Kubli S, Waeber B, Dalle-Ave A, et al. 2000. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol, 6:640-8.
38. Laasko M, Lehto S. 1997. Epidemiology of macrovascular disease in diatetes. Diab Rev, 5:294-315.
39. Laurent S, Cockcroft J, Van Bortel L, et al. 2006. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J, 27:2588-605.
40. Leurs PB, Stolk RP, Hamulyak K, et al. 2002. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care, 25:1340-5.
41. Libby P, Simon DI. 2001. Inflammation and thrombosis: the clot thickens. Circulation, 103:1718-20.
42. Lim SC, Caballero AE, Smakowski P, et al. 1999. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care, 22:1865-70.
43. McGill JB, Schneider DJ, Arfken CL, et al. 1994. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes, 43:104-9.
44. Morange PE, Renucci JF, Charles MA, et al. 2001. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost, 85:999-1003.
45. Morange PE, Simon C, Alessi MC, et al. 2004. Endothelial cell markers and the risk of coronary heart disease. Circulation, 109:1343-8.
46. Morris SJ, Shore AC, Tooke JE. 1995. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia, 38:1337-44.
47. Murray CJ, Lopez AD. 1996. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science, 274:740-43.
48. Naghavi M, Libby P, Falk E, et al.2003.. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation, 108:1772-8.
49. Natali A, Toschi E, Baldeweg S, et al. 2006. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes, 55:1133-40.
50. Nathan DM. 1993. Long-term complications of diabetes mellitus. N Engl J Med, 328:1676-85.
51. Pinkney JH, Stehouwer CD, Coppack SW, et al. 1997. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes, 46 (Suppl 2):S9-S13.
52. Pyorala M, Miettinen H, Halonen P, et al. 2000. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol, 20:538-44.
53. Reaven GM, Lithell H, Landsberg L. 1996. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 334:374-81.
54. Rigla M, Wagner AM, Borrell M, et al. 2006. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metab, 55:1437-42.
55. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-26.
56. Stansberry KB, Peppard HR, Babyak LM, et al. 1999. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care, 22:1549-54.
57. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, et al. 1999. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care, 22:2055-60.
58. Verma S, Anderson TJ. 2002. Fundamentals of endothelial function for the clinical cardiologist. Circulation, 105:546-9.
59. Verma S, Buchanan MR, Anderson TJ. 2003. Endothelial function testing as a biomarker of vascular disease. Circulation, 108:2054-9.
60. Vinik A, Erbas T, Park TS, et al. 2001. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care, 24:1468-75.
61. Waeber B, Feihl F, Ruilope L. 2001. Diabetes and hypertension. Blood Pressure, 10:311-21.
62. Waeber B, Feihl F. 2005. Oxidative stress: a pivotal link among cardiovascular risk factors? Curr Hypertens Rep, 7:229-30.
63. Wardell K, Naver HK, Nilsson GE, et al. 1993. The cutaneous vascular axon reflex in humans characterized by laser Doppler perfusion imaging. J Physiol, 460:185-99.
64. Wheatcroft SB, Williams IL, Shah AM, et al. 2003. Pathophysiological implications of insulin resistance on vascular endothelial function. Diab Med, 20:255-68.
65. Williams SB, Cusco JA, Roddy MA, et al. 1996. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol, 27:567-74.
66. Yano Y, Kitagawa N, Gabazza EC, et al. 2003. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab, 88:736-41.
67. Zenere BM, Arcaro G, Saggiani F, et al. 1995. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care, 18:975-82.